Insulet Corporation (PODD)

Market Cap	21.62B
Revenue (ttm)	2.36B
Net Income (ttm)	236.10M
Shares Out	70.39M
EPS (ttm)	3.32
PE Ratio	92.42
Forward PE	61.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,099,876
Open	303.55
Previous Close	303.55
Day's Range	299.83 - 312.99
52-Week Range	173.00 - 329.33
Beta	1.35
Analysts	Strong Buy
Price Target	324.68 (+5.73%)
Earnings Date	Aug 7, 2025

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is cont...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 15, 2007
• Employees: 3,900
• Stock Exchange: NASDAQ
• Ticker Symbol: PODD
• Website: https://www.insulet.com

Financial Performance

In 2024, Insulet's revenue was $2.07 billion, an increase of 22.07% compared to the previous year's $1.70 billion. Earnings were $418.30 million, an increase of 102.76%.

Analyst Summary

According to 19 analysts, the average rating for PODD stock is "Strong Buy." The 12-month stock price target is $324.68, which is an increase of 5.73% from the latest price.

Price Target

$324.68

(5.73% upside)

Analyst Consensus: Strong Buy